Boehringer Ingelheim


Global, independent biopharmaceutical company active in human and animal health. Large investor in research and development with capabilities spanning drug discovery, clinical development, regulatory submissions, biopharmaceutical manufacturing, vaccine development, and digital health solutions. Operates global clinical programs and partnerships across oncology, respiratory, cardio-renal-metabolic and other therapeutic areas.

Industries

Alternative Medicine
Biotechnology
Health Care
Health Diagnostics
Medical
Pharmaceutical
Pharmaceutical Manufacturing

Nr. of Employees

Very Large (1000+)

Boehringer Ingelheim


Products

ALPHA™

The only single-dose, seven-way clostridial vaccine with additional single-dose pinkeye protection.

ALPHA-CD

A bovine clostridial vaccine product from Boehringer Ingelheim Vetmedica GmbH.

ALPHA-7

A bovine clostridial vaccine product from Boehringer Ingelheim Vetmedica GmbH.

ENTERVENE

An animal health product for cattle from Boehringer Ingelheim.

EnterVene-d

Cattle respiratory and systemic vaccine indicated for the vaccination of healthy cattle 2 weeks or older to aid in the reduction of clinical disease and mortality due to Salmonella dublin.

CITADEL

Vaccine providing protection against five major Leptospira serovars and Campylobacter fetus to help protect against infertility, delayed conception, or abortion.

View All Products

Services

End-to-end clinical development services including protocol design, site network activation, global trial conduct and data collection.

Licensing, collaboration and asset-integration services to advance externally sourced or co-developed therapeutic programs into clinical development.

Development and commercialization of in-house digital tools aimed at patient safety and clinical workflows.

Large-scale production and contract manufacturing services for biologics and other biopharmaceuticals.

Expertise Areas

  • Clinical trial management
  • Pulmonary fibrosis research and development
  • Oncology drug development
  • Antibody-drug conjugate (ADC) development
  • Show More (6)

Key Technologies

  • Antibody-drug conjugates (ADCs)
  • Monoclonal antibody engineering
  • Small-molecule PDE4B inhibitors
  • Randomized double-blind placebo-controlled clinical trials
  • Show More (6)

News & Updates

Topline data show investigational preferential PDE4B inhibitor met the primary endpoint (absolute change in FVC at week 52 versus placebo); company to submit regulatory applications.

Global collaboration and license agreement to advance an antibody-drug conjugate asset into first-in-human studies.

Overview of the role of biomarker testing in personalizing treatment for non-small cell lung cancer.

An investigational PDE4B inhibitor program was granted Breakthrough Therapy designation by the US FDA for idiopathic pulmonary fibrosis.

Received positive opinions from the Committee for Medicinal Products for Veterinary Use for two avian influenza vaccine candidates.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.